Using a different model of joint inflammation, the mC04 monoclonal ACPA was previously shown to have an arthritis-accelerating effect.7 When ACPA was administered at the peak of disease, mC03-receiving mice recovered almost completely from joint inflammation 48 hours post-ACPA transfer (figure 1F). Here, PRTN3 is linked to arthritic joint disease.